13 GHP Q2 2024 grades. The new GALEAS™ Bladder test detects bladder cancer by picking up genetic markers in urine samples, which patients can now provide from the comfort of their own home. The sample is then posted for genetic analysis to the Informed Genomics lab, and results are shared with the patient’s doctor. This avoids the need for a cystoscopy – an uncomfortable hospital procedure that involves a camera being passed through the urethra to the bladder. In November 2023, Bupa partnered with Informed Genomics to become the first UK health insurer to cover the GALEAS Bladder test for its customers. Professor Rik Bryan, Professor in Urothelial Cancer Research, comments, “I am delighted to see our urine test now being implemented by Informed Genomics Ltd and adopted by healthcare providers such as Bupa. In parallel, and with the support of Cancer Research UK, my colleagues and I at the Bladder Cancer Research Centre at the University of Birmingham are focusing on designing and delivering clinical studies within a number of bladder cancer settings so that NHS adoption can follow suit.” Growing accessibility to genomic testing Genomics will play an increasingly significant role in healthcare for patients around the world, but to increase accessibility, a different approach is required when it comes to service delivery. A robust infrastructure that enables collaboration between public and private entities, allowing them to pool resources such as funding, infrastructure, and specialist knowledge, will help to give patients access to cutting-edge technologies and treatments that otherwise would not be available. Informed Genomics CEO, Simon Davis, says, “These collaborations work when both organisations are focused on the needs of the patient and share a commitment to putting quality at the heart of everything they do. We already have some fantastic projects lined up for 2024 and beyond and will continue to work with new and existing partners to help make our vision of transforming healthcare journeys for patients a reality.” Company: Informed Genomics Ltd Contact: Simon Davis, Chief Executive Officer Email: [email protected] Website: https://informedgenomics.com/ ealthcare partnerships are the key to unlocking access to genomic testing The benefits of genomic testing are widely recognised, enabling early diagnosis, personalised treatments, and improving outcomes for patients, as well as streamlining processes and delivering significant efficiencies to healthcare providers. By collaborating with like-minded healthcare and service providers across public and private sectors, Informed Genomics is successfully increasing capacity for genomic testing and helping to transform healthcare journeys for patients around the world. Public private partnerships in action Informed Genomics is the only private laboratory working with NHS England to help deliver the recently launched NHS Jewish BRCA Testing Programme, part of the NHS’ drive to detect cancer early when it is easier to treat. The genetic testing programme is targeting tens of thousands of people with Jewish ancestry who are more likely to carry a genetic fault that can increase the risk of developing some cancers. Over the next three years, the programme will offer any adult with Jewish ancestry a simple genetic saliva test to look for the presence of BRCA1 or BRCA2 faults, which increase the likelihood of developing certain cancers, including breast, ovarian, prostate, and pancreatic cancer. It is estimated that a fault in one of the BRCA genes affects around one in 40 Jewish people compared with one in 250 in the general population. Up to four in 10 ovarian cancers and one in 10 breast cancers in the Jewish community are caused by a BRCA mutation, but 90% of Jewish BRCA carriers are unaware they carry it. Working with Informed Genomics increases the programme’s capacity to test these large numbers in a cost-effective and efficient way. It also epitomises Informed Genomics’ mission to provide accessible genomic testing across all demographics and locations. Commercial partnerships for good Bladder cancer is the fifth most common cancer in the world – every year, 600,000 people receive a diagnosis and over 200,000 deaths are linked to the disease. Like many cancers, early diagnosis of the disease is crucial – more than 80 percent of people diagnosed at the earliest stage survive at least five years compared to less than 10 per cent diagnosed at the latest stage. Informed Genomics offers a pioneering genetic test for bladder cancer, developed to speed up detection of genetic mutations associated with 96 percent of bladder cancers at all stages and Recognised as our Most Innovative Genomic Testing Company 2024 – England, Informed Genomics is a UK-based accredited provider of innovative genomic cancer testing services and solutions to the NHS and private sector, and it is on a mission to make genomic testing accessible to all. Transforming Cancer Healthcare H Mar24532
RkJQdWJsaXNoZXIy MTUyMDQwMA==